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Statin hepatotoxicity and the dilemma of causality in rare hepatic adverse drug reactions
To the Editor:
In his editorial, Bader [1] highlights the problems associated with assessing statin-induced hepatotoxicity, a rare hepatic adverse drug reaction (ADR). However, the definitions of hepatotoxicity and idiosyncratic reactions are used by Bader in a confusing way. With the appraisal ''Yes! Statins can be given to liver patients'' Bader also creates the impression that statins are withheld from patients with liver disease [1] . At least outside the US, however, mainstream physicians including hepatologists never had a problem prescribing statins to their liver patients; uncertainty exists only how to proceed in cases of decompensated liver cirrhosis. Björnsson et al. [2] have clearly shown that statins can cause idiosyncratic hepatotoxicity. In general, drug hepatotoxicity refers to either of two different underlying reactions, namely the dose dependent, predictable, and hence intrinsic reaction, or the dose independent, unpredictable, and hence idiosyncratic one. Limiting ''hepatotoxicity'' to the dose dependent reaction leaves the reader with the impression that statins are not hepatotoxic due to lack of dose dependency [1] ; on the contrary, statin Letters to the Editor 702
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